Dr Meyer-Rath is a Research Associate Professor at the Department of Global Health of the Boston University School of Public Health. She is a physician and health economist working on the economics of HIV and COVID-19 in low- and middle-income countries. Her focus lies on modeling methods for economic evaluation, including infectious disease modeling and decision analysis, and translating research into recommendations for public policy. Before joining BUSPH she has worked in the Pediatrics Department of Charité University Hospital Berlin, at the World Health Organization and at the London School of Hygiene and Tropical Medicine.
Dr Meyer-Rath is based in Johannesburg where she works at the Health Economics and Epidemiology Research Office (HE2RO), a collaboration between Boston University and the University of the Witwatersrand. She holds a PhD in Health Economics from the London School of Hygiene and Tropical Medicine as well as a MD/PhD in Physiology from Free University Berlin.
Diversity, Equity, Inclusion and Accessibility
Early this year I was invited to co-chair a conference session on "Decolonising Health Economics" at the International Health Economics Association Conference. I tried to refuse, not thinking that as a highly privileged German national I could do the subject justice, but my co-chair, a Malawian health economist who I had mentored through her PhD, insisted. She invited me to talk about HE2RO's experience in building sustained academic health economics capacity in a middle-income country. This started my journey towards more consciously centering local, in particular first generation, staff in all activities. The notes under "Ad 7" above are in part a summary of that endeavour; of the four mentees mentioned, all are South African, two are previously disadvantaged, and all are first generation academics. Being involved in a first pan-African research project, the "UHCDigital" project funded by the German Research Foundation (DFG) continued the theme of making space (in brief, shutting up and stepping aside). Lastly, thinking through what kind of health modelling institute we want to build extended the theme of capacity building. I do believe we need to collectively move from building capacity individually, one-at-a-time, depending on our time and budget (there's a reason why "Capacity building" most often comes last in any funding proposal), towards helping to co-design, then build local institutions- then, once it is up and running, getting out. My joining the BUSPH DEIJ at the beginning of 2022 continues this journey.
Center Faculty Member
Boston University School of Public Health
HIV and TB estimation, mathematical modelling, and economic analysis to support national and sub-national HIV policy setting in South Africa
09/30/2020 - 12/31/2023 (Subcontract PI)University of Cape Town Bill & Melinda Gates
To Support a consortium of modelers to inform the planning of HIV programs in Sub-Saharan Africa to understand the impact of current and future interventions
10/01/2021 - 09/30/2023 (Subcontract PI)WITS Health Consortium (PTY) LTD Bill & Melinda Gates
COVID-19 priority vaccine modelling for South Africa and beyond
08/12/2021 - 01/31/2023 (Subcontract PI)WITS Health Consortium (PTY) LTD Bill & Melinda Gates
Rapid Screening for Complex Chronic Conditions (Taxi Rank project)
07/01/2021 - 11/30/2022 (Multi-PI)
PI: Gesine Meyer-Rath, MD, PhDFoundation for Innovative New Diagnostics (FIND)
Economic Impact of HIV Policy Briefs
11/14/2019 - 04/30/2022 (PI)Bill and Melinda Gates Foundation
Enhancing the evidence-base for HIV self-testing in young men
04/17/2018 - 12/31/2020 (Subcontract PI)WITS Health Consortium (PTY) LTD Bill & Melinda Gates
Prospective costing exercises for HIV in high prevalence countries
01/01/2020 - 10/30/2020 (Subcontract PI)President & Fellows of Harvard College on behalf of Harvard Medical School Bill & Melinda Gates
Identifying optimal HIV testing strategies to achieve high levels of HIV diagnosis in South Africa
09/01/2016 - 07/31/2017 (Subcontract PI)Imperial College Bill & Melinda Gates
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 68 results.
Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver D, Kripke K, Revill P, Boily MC, Meyer-Rath G, Taramusi I, Lundgren JD, van Oosterhout JJ, Kuritzkes D, Schaefer R, Siedner MJ, Schapiro J, Delany-Moretlwe S, Landovitz RJ, Flexner C, Jordan M, Venter F, Radebe M, Ripin D, Jenkins S, Resar D, Amole C, Shahmanesh M, Gupta RK, Raizes E, Johnson C, Inzaule S, Shafer R, Warren M, Stansfield S, Paredes R, Phillips AN. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 Jan 12. PMID: 36642087; DOI: 10.1016/S2352-3018(22)00365-4;
Bansi-Matharu L, Mudimu E, Martin-Hughes R, Hamilton M, Johnson L, Ten Brink D, Stover J, Meyer-Rath G, Kelly SL, Jamieson L, Cambiano V, Jahn A, Cowan FM, Mangenah C, Mavhu W, Chidarikire T, Toledo C, Revill P, Sundaram M, Hatzold K, Yansaneh A, Apollo T, Kalua T, Mugurungi O, Kiggundu V, Zhang S, Nyirenda R, Phillips A, Kripke K, Bershteyn A. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023 Feb; 11(2):e244-e255. PMID: 36563699; DOI: 10.1016/S2214-109X(22)00515-0;
Masuku SD, Lekodeba N, Meyer-Rath G. The costs of interventions for type 2 diabetes mellitus, hypertension and cardiovascular disease in South Africa - a systematic literature review. BMC Public Health. 2022 Dec 12; 22(1):2321. PMID: 36510178; PMCID: PMC9743545; DOI: 10.1186/s12889-022-14730-4;
Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 Dec; 9(12):e857-e867.View Related Profiles. PMID: 36356603; PMCID: PMC9708606; DOI: 10.1016/S2352-3018(22)00251-X;
Bershteyn A, Jamieson L, Kim HY, Platais I, Milali MP, Mudimu E, Ten Brink D, Martin-Hughes R, Kelly SL, Phillips AN, Bansi-Matharu L, Cambiano V, Revill P, Meyer-Rath G, Nichols BE. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 09; 10(9):e1298-e1306.View Related Profiles. PMID: 35961353; PMCID: PMC9380252; DOI: 10.1016/S2214-109X(22)00310-2;
Silal SP, Groome MJ, Govender N, Pulliam JRC, Ramadan OP, Puren A, Jassat W, Leonard E, Moultrie H, Meyer-Rath KG, Ramkrishna W, Langa T, Furumele T, Moonasar D, Cohen C, Walaza S. Leveraging epidemiology as a decision support tool during the COVID-19 epidemic in South Africa. S Afr Med J. 2022 May 31; 112(5b):361-365. PMID: 35783465; PMCID: PMC7612950; DOI: 10.7196/SAMJ.2022.v112i5b.16061;
Phillips AN, Bershteyn A, Revill P, Bansi-Matharu L, Kripke K, Boily MC, Martin-Hughes R, Johnson LF, Mukandavire Z, Jamieson L, Meyer-Rath G, Hallett TB, Ten Brink D, Kelly SL, Nichols BE, Bendavid E, Mudimu E, Taramusi I, Smith J, Dalal S, Baggaley R, Crowley S, Terris-Prestholt F, Godfrey-Faussett P, Mukui I, Jahn A, Case KK, Havlir D, Petersen M, Kamya M, Koss CA, Balzer LB, Apollo T, Chidarikire T, Mellors JW, Parikh UM, Godfrey C, Cambiano V. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 May; 9(5):e353-e362.View Related Profiles. PMID: 35489378; PMCID: PMC9065367; DOI: 10.1016/S2352-3018(22)00029-7;
Johnson LF, Meyer-Rath G, Dorrington RE, Puren A, Seathlodi T, Zuma K, Feizzadeh A. The Effect of HIV Programs in South Africa on National HIV Incidence Trends, 2000-2019. J Acquir Immune Defic Syndr. 2022 Jun 01; 90(2):115-123. PMID: 35125471
Jamieson L, Serenata C, Makhubele L, Sokhela S, Mashabane N, Akpomiemie G, Johnson LF, Venter WDF, Meyer-Rath G. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182. PMID: 34848584
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
2010 International AIDS Society/ ANRS:
Young Investigator Award